Innovative Diabetes Management: Navigating Treatment, Financial Constraints, and Patient-Centered Care
DOI:
https://doi.org/10.5457/ams.v55i1.821Keywords:
diabetes, inertia, insulin, GLP-1 ra, obesityAbstract
Diabetes mellitus, a chronic and progressive disease, often leads to severe complications that compromise patients' quality of life and reduce life expectancy. This case study presents a 54-year-old female patient with type 2 diabetes mellitus, diagnosed 13 years ago, who experienced frequent hypoglycemia despite achieving satisfactory glycemic control. The patient's treatment regimen included basal-bolus insulin therapy, oral metformin, and rigorous self-monitoring of blood glucose, yet she expressed dissatisfaction with her weight and overall well-being. To address these concerns, liraglutide, a GLP-1 receptor agonist, was introduced into her treatment plan. Liraglutide was selected for its ability to maintain glycemic control, reduce hypoglycemic episodes, facilitate weight loss, and offer cardiovascular protection. Despite initial out-of-pocket costs due to lack of insurance coverage, the patient experienced a marked improvement in glycemic variability, reduced insulin dependence, decreased frequency of glucose monitoring, and weight reduction after just two months of therapy. Her treatment evolved with insurance coverage of GLP-1 receptor agonists, leading to a switch to dulaglutide. This case underscores the importance of individualized, holistic diabetes management that addresses glycemic control and prioritizes patient satisfaction and quality of life. It also highlights the impact of medication costs and insurance coverage on treatment accessibility and long-term outcomes.
References
Komenda, P.; Ferguson, T.W.; Macdonald, K.; Rigatto, C.; Koolage, C.; Sood, M.M.; Tangri, N. Cost-effectiveness of primary screening for CKD: A systematic review. Am. J. Kidney Dis. 2014, 63, 789–797.
Steinke, J.M. The natural progression of kidney injury in young type 1 diabetic patients. Curr. Diab. Rep. 2009, 9, 473–479.
Bourne RRA, Jonas JB, Bron AM, Cicinelli MV, Das A, Flaxman SR, et al. Prevalence and causes of vision loss in high-income countries and Eastern and Central Europe in 2015: magnitude, temporal trends and projections. Br J Ophthalmol. 2018;102:575–585. doi: 10.1136/bjophthalmol-2017-311258.
Elisa Dal Canto, Antonio Ceriello, Lars Rydén, Marc Ferrini, Tina B Hansen, Oliver Schnell, Eberhard Standl, Joline WJ Beulens, Diabetes as a cardiovascular risk factor: An overview of global trends of macro and micro vascular complications, European Journal of Preventive Cardiology, Volume 26, Issue 2_suppl, 1 December 2019, Pages 25–32, https://doi.org/10.1177/20474873198783715.
S.P. Marso, G.H. Daniels, K. Brown-Frandsen, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes New Engl. J. Med., 375 (4) (2016), pp. 311-322, 10.1056/NEJMoa1603827.
G Ferrannini, H.C Gerstein, H.M Colhoun, G.R Dagenais, R Diaz, L Dyal, M Lakshmanan, L Mellbin, J Probstfield, M.C Riddle, J.E Shaw, L Ryden, REWIND Investigators , Dulaglutide is cardioprotective with or without background metformin in patients with diabetes and established or high risk for coronary vascular disease. A subgroup analysis of the REWIND Trial, European Heart Journal, Volume 41, Issue Supplement_2, November 2020, ehaa946.3353, https://doi.org/10.1093/ehjci/ehaa946.3353.
Harris SB, Cheng AYY, Davies MJ, et al. Person-Centered, Outcomes-Driven Treatment: A New Paradigm for Type 2 Diabetes in Primary Care. Arlington (V.A.): American Diabetes Association; 2020 May. FIGURE 3, [Decision cycle for person-centered glycemic...]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK559432/figure/F3/ doi: 10.2337/db2020-02.
American Diabetes Association Professional Practice Committee; Summary of Revisions: Standards of Care in Diabetes—2024. Diabetes Care 1 January 2024; 47 (Supplement_1): S5–S10. https://doi.org/10.2337/dc24-SREV.
Downloads
Published
Issue
Section
License
Copyright transfer
The listed authors warrant that they are the authors and sole owners of the submitted manuscript. The authors also warrant that the work is original; that it has not been previously published in print or electronic format and is not under consideration by another publisher or electronic medium; that it has not been previously transferred, assigned, or otherwise encumbered; and that the authors have full power to grant such rights. With respect to the results of this work, the manuscript of this or substantially similar content will not be submitted to any other journal until the review process in the Acta Medica Salinianana has been officially completed (acceptance or rejection of the manuscript). The paper will not be withdrawn from the review process by the Acta Medica Saliniana Editorial Board until the review process is completed. The authors will comply with the requests of the Acta Medica Saliniana Editors and reviewers to improve the paper for publication. The eventual disagreements will be submitted in a written form; the authors are aware that the disagreement(s) with the Acta Medica Saliniana requests may result in the rejection of the manuscript. The authors hereby grant to the Acta Medica Saliniana the right to edit, revise, abridge, and condense the manuscript. If the manuscript is accepted for publication in the Acta Medica Saliniana, the authors hereby transfer the copyright of the paper to the Acta Medica Saliniana. The authors permit the Acta Medica Saliniana to allow third parties to copy any part of the journal without asking for permission, provided that the reference to the source is given. For papers with more than one author: All other co-authors agree to allow the corresponding author to make decisions regarding prepublication release of the information in the paper to the media, federal agencies, or both.
